Symbols

LXRX

Lexicon Pharmaceuticals·NASDAQ

--(--)

LXRX fundamentals

LXRX Q4 2025 Earnings

Lexicon Pharmaceuticals (LXRX) released its earnings on Mar 5, 2026: revenue was 5.49M (YoY -79.31%), beat estimates; EPS was -0.04 (YoY +55.56%), beat estimates.

Revenue / YoY

5.49M

-79.31%

EPS / YoY

-0.04

+55.56%

Report date

Mar 5, 2026

LXRX Earnings Call Summary for Q4,2025

HCM Trial Momentum: Sotagliflozin Phase III >50% enrolled, targeting mid-2026 completion with potential 2027 data.
T1D Regulatory Path: Zynquista NDA resubmission expected in 2026 with STENO1 data; first oral therapy for T1D if approved.
Partnership Progress: Pilavapadin Phase III discussions advanced; LX9851 on track for $20M milestone in 2026.
Financial Strength: $200M+ cash post-capital raise; 2026 expenses guided to $100-110M with disciplined spending.

Earnings

EPS

Revenue

Revenue & Expenses

LXRX has released its 2025 Q4 earnings report, with revenue of 5.49M, reflecting a YoY change of -79.31%, and net profit of -15.53M, showing a YoY change of 54.01%. The Sankey diagram below clearly presents LXRX's revenue sources and cost distribution.

Key Indicators

Lexicon Pharmaceuticals (LXRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Lexicon Pharmaceuticals (LXRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Lexicon Pharmaceuticals (LXRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Lexicon Pharmaceuticals (LXRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown